$1.53
-0.02-1.29%
At close: -
$1.53
0.000.00%
After Hours: 4:33 PM EDT
Comments
Loading...
Outlook Therapeutics Analyst Ratings and Price Targets | NASDAQ:OTLK | Benzinga
Outlook Therapeutics Inc has a consensus price target of $7.32 based on the ratings of 9 analysts. The high is $24 issued by Ascendiant Capital on February 24, 2025. The low is $1 issued by Cantor Fitzgerald on August 30, 2023. The 3 most-recent analyst ratings were released by Ascendiant Capital, HC Wainwright & Co., and Chardan Capital on February 24, 2025, February 18, 2025, and February 18, 2025, respectively. With an average price target of $10 between Ascendiant Capital, HC Wainwright & Co., and Chardan Capital, there's an implied 553.59% upside for Outlook Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Ascendiant Capital
HC Wainwright & Co.
Chardan Capital
Guggenheim
BTIG
1calculated from analyst ratings
Analyst Ratings for Outlook Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/24/2025 | Buy Now | 1468.63% | Ascendiant Capital | Edward Woo53% | $33 → $24 | Maintains | Buy | Get Alert |
| 02/18/2025 | Buy Now | 96.08% | HC Wainwright & Co. | Douglas Tsao53% | $30 → $3 | Maintains | Buy | Get Alert |
| 02/18/2025 | Buy Now | 96.08% | Chardan Capital | Daniil Gataulin43% | $3 → $3 | Maintains | Neutral | Get Alert |
| 01/17/2025 | Buy Now | 684.31% | Guggenheim | Eddie Hickman52% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 01/17/2025 | Buy Now | 1860.78% | HC Wainwright & Co. | Douglas Tsao53% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 12/02/2024 | Buy Now | — | Chardan Capital | Daniil Gataulin43% | — | Downgrade | Buy → Neutral | Get Alert |
| 11/29/2024 | Buy Now | 488.24% | BTIG | Julian Harrison40% | $50 → $9 | Maintains | Buy | Get Alert |
| 11/29/2024 | Buy Now | 1860.78% | HC Wainwright & Co. | Douglas Tsao53% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/18/2024 | Buy Now | 3167.97% | BTIG | Julian Harrison40% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2024 | Buy Now | 2056.86% | Ascendiant Capital | Edward Woo53% | $35 → $33 | Maintains | Buy | Get Alert |
| 08/16/2024 | Buy Now | 3364.05% | Chardan Capital | Daniil Gataulin43% | $53 → $53 | Maintains | Buy | Get Alert |
| 08/15/2024 | Buy Now | 1860.78% | HC Wainwright & Co. | Douglas Tsao53% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2024 | Buy Now | 1860.78% | HC Wainwright & Co. | Douglas Tsao53% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 3167.97% | BTIG | Julian Harrison40% | → $50 | Upgrade | Neutral → Buy | Get Alert |
| 03/25/2024 | Buy Now | 1860.78% | HC Wainwright & Co. | Douglas Tsao53% | $1.5 → $30 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | 96.08% | Chardan Capital | Daniil Gataulin43% | → $60 | Upgrade | Neutral → Buy | Get Alert |
| 01/25/2024 | Buy Now | 30.72% | Guggenheim | Eddie Hickman52% | → $40 | Upgrade | Neutral → Buy | Get Alert |
| 01/25/2024 | Buy Now | 2.61% | Brookline Capital | Kemp Dolliver27% | → $31.4 | Upgrade | Hold → Buy | Get Alert |
| 12/29/2023 | Buy Now | 30.72% | Ascendiant Capital | Edward Woo53% | $30 → $40 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | 226.8% | Capital One | Zegbeh Jallah65% | → $100 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/03/2023 | Buy Now | 30.72% | HC Wainwright & Co. | Douglas Tsao53% | $20 → $40 | Maintains | Buy | Get Alert |
| 08/31/2023 | Buy Now | — | Chardan Capital | Daniil Gataulin43% | — | Downgrade | Buy → Neutral | Get Alert |
| 08/31/2023 | Buy Now | -34.64% | HC Wainwright & Co. | Douglas Tsao53% | → $20 | Downgrade | Buy → Neutral | Get Alert |
| 08/30/2023 | Buy Now | — | Brookline Capital | Kumaraguru Raja19% | — | Downgrade | Buy → Hold | Get Alert |
| 08/30/2023 | Buy Now | -34.64% | Cantor Fitzgerald | Kristen Kluska69% | $90 → $20 | Downgrade | Overweight → Neutral | Get Alert |
| 08/30/2023 | Buy Now | — | BTIG | Julian Harrison40% | — | Downgrade | Buy → Neutral | Get Alert |
| 08/15/2023 | Buy Now | 226.8% | HC Wainwright & Co. | Douglas Tsao53% | → $100 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 553.59% | Chardan Capital | Daniil Gataulin43% | → $200 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2023 | Buy Now | 226.8% | HC Wainwright & Co. | Douglas Tsao53% | → $100 | Reiterates | Buy → Buy | Get Alert |
| 07/13/2023 | Buy Now | 226.8% | Capital One | Zegbeh Jallah65% | → $100 | Initiates | → Overweight | Get Alert |
| 05/16/2023 | Buy Now | 553.59% | Chardan Capital | Daniil Gataulin43% | → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 226.8% | HC Wainwright & Co. | Douglas Tsao53% | → $100 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2023 | Buy Now | 226.8% | Guggenheim | Eddie Hickman52% | → $100 | Initiates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | 226.8% | HC Wainwright & Co. | Douglas Tsao53% | → $100 | Maintains | Buy | Get Alert |
| 02/06/2023 | Buy Now | 161.44% | Cantor Fitzgerald | Kristen Kluska69% | → $80 | Initiates | → Overweight | Get Alert |
| 01/06/2023 | Buy Now | 226.8% | HC Wainwright & Co. | Douglas Tsao53% | $120 → $100 | Maintains | Buy | Get Alert |
| 10/31/2022 | Buy Now | 357.52% | BTIG | Julian Harrison40% | → $140 | Initiates | → Buy | Get Alert |
| 09/13/2022 | Buy Now | 553.59% | Chardan Capital | Daniil Gataulin43% | → $200 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Outlook Therapeutics (OTLK) stock?
The latest price target for Outlook Therapeutics (NASDAQ:OTLK) was reported by Ascendiant Capital on February 24, 2025. The analyst firm set a price target for $24.00 expecting OTLK to rise to within 12 months (a possible 1468.63% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Outlook Therapeutics (OTLK)?
The latest analyst rating for Outlook Therapeutics (NASDAQ:OTLK) was provided by Ascendiant Capital, and Outlook Therapeutics maintained their buy rating.
When was the last upgrade for Outlook Therapeutics (OTLK)?
The last upgrade for Outlook Therapeutics Inc happened on March 27, 2024 when BTIG raised their price target to $50. BTIG previously had a neutral for Outlook Therapeutics Inc.
When was the last downgrade for Outlook Therapeutics (OTLK)?
The last downgrade for Outlook Therapeutics Inc happened on December 2, 2024 when Chardan Capital changed their price target from N/A to N/A for Outlook Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Outlook Therapeutics (OTLK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Outlook Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Outlook Therapeutics was filed on February 24, 2025 so you should expect the next rating to be made available sometime around February 24, 2026.
Is the Analyst Rating Outlook Therapeutics (OTLK) correct?
While ratings are subjective and will change, the latest Outlook Therapeutics (OTLK) rating was a maintained with a price target of $33.00 to $24.00. The current price Outlook Therapeutics (OTLK) is trading at is $1.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
